What’s Happening in the RRP Community
What’s Happening in the RRP Community
Stay informed on the latest developments in RRP research, treatment advances, clinical trial opportunities, and advocacy efforts. This is your source for news that matters to patients, caregivers, and clinicians navigating the evolving landscape of recurrent respiratory papillomatosis care.
New Study Confirms What Patients Have Been Saying: Bevacizumab Offers a Better Quality of Life
A new study comparing patient experiences with surgery and systemic bevacizumab found that 83% of patients preferred bevacizumab and reported better voice, breathing, less pain, and improved mental health. Here's what the research found.
Clinical Trial: Pembrolizumab and Lenvatinib for RRP With Pulmonary Involvement
A new clinical trial led by Dr. Sarah Pai is investigating combination immunotherapy for adults with RRP that has spread to the lungs. Learn about the study and how to participate.
New Study Examines the Patient Perspective of Living with Recurrent Respiratory Papillomatosis
A newly published study in The Laryngoscope draws on data from the RRPF/CoRDS Patient Registry to quantify what our community has long known: RRP impacts far more than the airway. Here's what the research found.
First Patients Dosed With Papzimeos: A Historic Milestone for the RRP Community
After years of advocacy and research, the first patients have now received doses of Papzimeos. RRPF President Kim McClellan reflects on what this historic moment means for our community.
Update on INO-3017 FDA Review and RRPF Advocacy
INOVIO's Biologics License Application for INO-3017 has been accepted by the FDA. RRPF shares an update on the review process and our advocacy for the accelerated approval pathway.
FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
INOVIO announced that the FDA has accepted its Biologics License Application for INO-3107 for review as a potential treatment for adults with RRP. Here's what this milestone means for our community.
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
INOVIO announced it has completed the rolling submission of its Biologics License Application for INO-3107. RRPF President Kim McClellan shares what this milestone means for our community.
Hope Realized: FDA Approves Papzimeos for Adults with Recurrent Respiratory Papillomatosis
The FDA has approved Papzimeos, the first and only treatment for adults with RRP. RRPF celebrates this historic milestone and reflects on what it means for our community.